Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07134088 · ClinicalTrials.gov registry record · Phase 1
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
A Phase 1 study of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
- 2
- Study locations
NCT07134088 is a Phase 1 study of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Amgen. The registered enrollment target is 104 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT07134088, a Phase 1 study of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
Conditions Studied
Interventions
- DRUG Blinatumomab
Study Locations (2)
Tennessee
- St Jude Childrens Research Hospital - Memphis
Kanagawa
- Kanagawa Childrens Medical Center - Yokohami-shi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2025-12-08 |
| Est. Completion | 2030-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07134088
The ClinicalTrials.gov registry entry for NCT07134088 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Blinatumomab is the first listed.
NCT07134088 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Tennessee, Kanagawa.
Frequently Asked Questions
What is clinical trial NCT07134088 about?
NCT07134088 is a clinical study titled "A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia". The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
What is the current status of trial NCT07134088?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2025-12-08. Estimated completion is 2030-06-18.
What conditions does trial NCT07134088 study?
This clinical trial studies the following conditions: Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT07134088?
The interventions under investigation include: Blinatumomab (DRUG).
Who is sponsoring clinical trial NCT07134088?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07134088 being conducted?
This trial has 2 study locations across Tennessee, Kanagawa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
All registered trials for this condition
Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
All registered trials for this condition
Tennessee
All trials with a study site in Tennessee
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.